2025 ICD-10-CM Diagnosis Code C81.3

by

Lymphocyte depleted Hodgkin lymphoma

  • C81.3 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2025 edition of ICD-10-CM C81.3 became effective on October 1, 2024.
  • This is the American ICD-10-CM version of C81.3 – other international versions of ICD-10 C81.3 may differ.

Applicable To

  • Lymphocyte depleted classical Hodgkin lymphoma

The following code(s) above C81.3 contain annotation back-references

 that may be applicable to C81.3:

  • C00-D49  Neoplasms
  • C81-C96  Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C81  Hodgkin lymphoma

Clinical Information

  • A diffuse form of classical hodgkin lymphoma which is rich in hodgkin and reed-sternberg cells and/or depleted in non-neoplastic lymphocytes. Historically, the clinical course of this type of hodgkin lymphoma was aggressive. With current therapy, the course is comparable to patients with other subtypes of classical hodgkin lymphoma. Most patients present with advanced stage disease (stage iii or iv) and b-symptoms. (who, 2001)

Code History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): Revised code
    • New description: Lymphocyte depleted Hodgkin lymphoma
    • 2016 description: Lymphocyte depleted classical Hodgkin lymphoma
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change
  • 2025 (effective 10/1/2024): No change

Diagnosis Index entries containing back-references to C81.3:

error: Content is protected !!